Zacks.com on MSN20h
NVO's Rybelsus Meets Primary Goal in MACE Study for Diabetes PatientsA late-stage study shows that Novo Nordisk's oral semaglutide, Rybelsus, cuts the risk of MACE by 14% in T2D patients ...
Seeking Alpha on MSN18h
Novo's Rybelsus results may not be clinically meaningful, Bernstein saysBernstein said Novo Nordisk (NVO) study results that showed certain Rybelsus users had a 14% risk reduction for major ...
WEIGHT-LOSS jabs are the most talked about drugs of the moment. And with new studies popping up almost every week revealing ...
The agency posted documents this week that the drugmaker had requested the drug be placed on the FDA's "Demonstrable ...
3hon MSN
Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and prohibitively expensive once compounding pharmacies are no longer producing it.
There are a few. Ozempic and other semaglutide medications can come with uncomfortable side effects —like nausea, diarrhea, ...
Research hints that medications like Zepbound and Wegovy could provide new ways to treat opioid and alcohol abuse.
GlobalData on MSN20h
Oxford Medical Products touts positive safety data for ‘mechanical’ weight loss pillThe company is eyeing a pivotal trial for its dual-polymer hydrogel stomach implant following promising first-in-human trial ...
SURVEY SAYS: Just 18% of the health-care plans sponsored by employers with 200 workers or more cover such drugs, according to ...
Earlier this month, WeightWatchers made the extraordinary announcement that it would be offering its own version of the 'fat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback